Ten of 16 patients with large B cell lymphoma with progressive disease after CAR19 treatment had absent or low CD19.
[Nature Medicine]
6445212 RF5BSW5T items 1 apa 0 default asc 1 164991 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-a44d246e1f9269f0e8739e6df2c335e6%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22RF5BSW5T%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Spiegel%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESpiegel%2C%20J.%20Y.%2C%20Patel%2C%20S.%2C%20Muffly%2C%20L.%2C%20Hossain%2C%20N.%20M.%2C%20Oak%2C%20J.%2C%20Baird%2C%20J.%20H.%2C%20Frank%2C%20M.%20J.%2C%20Shiraz%2C%20P.%2C%20Sahaf%2C%20B.%2C%20Craig%2C%20J.%2C%20Iglesias%2C%20M.%2C%20Younes%2C%20S.%2C%20Natkunam%2C%20Y.%2C%20Ozawa%2C%20M.%20G.%2C%20Yang%2C%20E.%2C%20Tamaresis%2C%20J.%2C%20Chinnasamy%2C%20H.%2C%20Ehlinger%2C%20Z.%2C%20Reynolds%2C%20W.%2C%20%26%23x2026%3B%20Miklos%2C%20D.%20B.%20%282021%29.%20CAR%20T%20cells%20with%20dual%20targeting%20of%20CD19%20and%20CD22%20in%20adult%20patients%20with%20recurrent%20or%20refractory%20B%20cell%20malignancies%3A%20a%20phase%201%20trial.%20%3Ci%3ENature%20Medicine%3C%5C%2Fi%3E%2C%201%26%23x2013%3B13.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-021-01436-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-021-01436-0%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DRF5BSW5T%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CAR%20T%20cells%20with%20dual%20targeting%20of%20CD19%20and%20CD22%20in%20adult%20patients%20with%20recurrent%20or%20refractory%20B%20cell%20malignancies%3A%20a%20phase%201%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%20Y.%22%2C%22lastName%22%3A%22Spiegel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shabnum%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lori%22%2C%22lastName%22%3A%22Muffly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nasheed%20M.%22%2C%22lastName%22%3A%22Hossain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Oak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20H.%22%2C%22lastName%22%3A%22Baird%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20J.%22%2C%22lastName%22%3A%22Frank%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Parveen%22%2C%22lastName%22%3A%22Shiraz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bita%22%2C%22lastName%22%3A%22Sahaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliana%22%2C%22lastName%22%3A%22Craig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Iglesias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheren%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasodha%22%2C%22lastName%22%3A%22Natkunam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20G.%22%2C%22lastName%22%3A%22Ozawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Tamaresis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harshini%22%2C%22lastName%22%3A%22Chinnasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zach%22%2C%22lastName%22%3A%22Ehlinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Warren%22%2C%22lastName%22%3A%22Reynolds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Lynn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Caterina%22%2C%22lastName%22%3A%22Rotiroti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolaos%22%2C%22lastName%22%3A%22Gkitsas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally%22%2C%22lastName%22%3A%22Arai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Lowsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robbie%20G.%22%2C%22lastName%22%3A%22Majzner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Everett%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20S.%22%2C%22lastName%22%3A%22Negrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20R.%22%2C%22lastName%22%3A%22Rezvani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Surbhi%22%2C%22lastName%22%3A%22Sidana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Shizuru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wen-Kai%22%2C%22lastName%22%3A%22Weng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chelsea%22%2C%22lastName%22%3A%22Mullins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allison%22%2C%22lastName%22%3A%22Jacob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilan%22%2C%22lastName%22%3A%22Kirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Bazzano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jing%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%22%2C%22lastName%22%3A%22Mackay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20J.%22%2C%22lastName%22%3A%22Bornheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liora%22%2C%22lastName%22%3A%22Schultz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sneha%22%2C%22lastName%22%3A%22Ramakrishna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%20L.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katherine%20A.%22%2C%22lastName%22%3A%22Kong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nirali%20N.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haiying%22%2C%22lastName%22%3A%22Qin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%22%2C%22lastName%22%3A%22Fry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Feldman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Crystal%20L.%22%2C%22lastName%22%3A%22Mackall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20B.%22%2C%22lastName%22%3A%22Miklos%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20impressive%20progress%2C%20more%20than%2050%25%20of%20patients%20treated%20with%20CD19-targeting%20chimeric%20antigen%20receptor%20T%20cells%20%28CAR19%29%20experience%20progressive%20disease.%20Ten%20of%2016%20patients%20with%20large%20B%20cell%20lymphoma%20%28LBCL%29%20with%20progressive%20disease%20after%20CAR19%20treatment%20had%20absent%20or%20low%20CD19.%20Lower%20surface%20CD19%20density%20pretreatment%20was%20associated%20with%20progressive%20disease.%20To%20prevent%20relapse%20with%20CD19%5Cu2212%20or%20CD19lo%20disease%2C%20we%20tested%20a%20bispecific%20CAR%20targeting%20CD19%20and%5C%2For%20CD22%20%28CD19-22.BB.z-CAR%29%20in%20a%20phase%20I%20clinical%20trial%20%28NCT03233854%29%20of%20adults%20with%20relapsed%5C%2Frefractory%20B%20cell%20acute%20lymphoblastic%20leukemia%20%28B-ALL%29%20and%20LBCL.%20The%20primary%20end%20points%20were%20manufacturing%20feasibility%20and%20safety%20with%20a%20secondary%20efficacy%20end%20point.%20Primary%20end%20points%20were%20met%3B%2097%25%20of%20products%20met%20protocol-specified%20dose%20and%20no%20dose-limiting%20toxicities%20occurred%20during%20dose%20escalation.%20In%20B-ALL%20%28n%5Cu2009%3D%5Cu200917%29%2C%20100%25%20of%20patients%20responded%20with%2088%25%20minimal%20residual%20disease-negative%20complete%20remission%20%28CR%29%3B%20in%20LBCL%20%28n%5Cu2009%3D%5Cu200921%29%2C%2062%25%20of%20patients%20responded%20with%2029%25%20CR.%20Relapses%20were%20CD19%5Cu2212%5C%2Flo%20in%2050%25%20%285%20out%20of%2010%29%20of%20patients%20with%20B-ALL%20and%2029%25%20%284%20out%20of%2014%29%20of%20patients%20with%20LBCL%20but%20were%20not%20associated%20with%20CD22%5Cu2212%5C%2Flo%20disease.%20CD19%5C%2F22-CAR%20products%20demonstrated%20reduced%20cytokine%20production%20when%20stimulated%20with%20CD22%20versus%20CD19.%20Our%20results%20further%20implicate%20antigen%20loss%20as%20a%20major%20cause%20of%20CAR%20T%20cell%20resistance%2C%20highlight%20the%20challenge%20of%20engineering%20multi-specific%20CAR%20T%20cells%20with%20equivalent%20potency%20across%20targets%20and%20identify%20cytokine%20production%20as%20an%20important%20quality%20indicator%20for%20CAR%20T%20cell%20potency.%22%2C%22date%22%3A%222021-07-26%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41591-021-01436-0%22%2C%22ISSN%22%3A%221546-170X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01436-0%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-07-26T17%3A11%3A54Z%22%7D%7D%5D%7D
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, Y., Ozawa, M. G., Yang, E., Tamaresis, J., Chinnasamy, H., Ehlinger, Z., Reynolds, W., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 1–13. https://doi.org/10.1038/s41591-021-01436-0 Cite